Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N.
Fizazi K, et al. Among authors: di santo n.
Nat Med. 2024 May;30(5):1505. doi: 10.1038/s41591-024-02835-9.
Nat Med. 2024.
PMID: 38297094
Free PMC article.
No abstract available.